Mattias Ivarsson is committed to fighting a nasty bacterium at the root of many hospital-acquired infections. This article describes the story behind Inositec’s technology and CEO.
10th November 2014
Categories
Most Recent
- Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
- Preclinical work on calcium oxalate inhibitors for renal indications published
- Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
- Discovery work on Clostridium difficile toxin inhibitors published
- Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates